Sign In
Last checked at 
30 May 2019 07:00
30 May 2019 |
Futura Medical plc (AIM: FUM)
("Futura" or "the Company")
Block Listing Update
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).
The table below provides further detail.
Name of company: | Futura Medical plc | ||||||||||||||||||
Name of scheme(s): | Unapproved Share Option Scheme ("USOS") Unapproved Share Incentive Scheme ("USIS") EMI Share Option Scheme ("EMI") | ||||||||||||||||||
Period of return: | From: | 1 December 2018 | |||||||||||||||||
To: | 30 May 2019 | ||||||||||||||||||
Number and class of securities not issued under the scheme(s) at beginning of period |
USOS: |
1,993,875 | |||||||||||||||||
USIS: | 425,000 | ||||||||||||||||||
EMI: | 3,806,125 | ||||||||||||||||||
Total: | 6,225,000 | ||||||||||||||||||
Number and class of securities admitted to the scheme(s) in the period | USOS: | - | |||||||||||||||||
USIS: | - | ||||||||||||||||||
EMI: | - | ||||||||||||||||||
Total: | - | ||||||||||||||||||
Number of securities issued under the scheme(s) during the period | USOS: | - | |||||||||||||||||
USIS: | - | ||||||||||||||||||
EMI: | - | ||||||||||||||||||
Total: | - | ||||||||||||||||||
Number of securities lapsed under the scheme(s) during the period | USOS: | - | |||||||||||||||||
USIS: | - | ||||||||||||||||||
EMI: | - | ||||||||||||||||||
Total: | - | ||||||||||||||||||
Balance of securities under the scheme(s) not yet issued at the end of the period | USOS: | 1,993,875 | |||||||||||||||||
USIS: | 425,000 | ||||||||||||||||||
EMI: | 3,806,125 | ||||||||||||||||||
Total: | 6,225,000 | ||||||||||||||||||
| |||||||||||||||||||
Number and class of securities originally admitted and the date of admission |
USOS: |
| |||||||||||||||||
USOS Total: | 3,882,912 | ||||||||||||||||||
USIS: |
|
| |||||||||||||||||
USIS Total: | 425,000 | ||||||||||||||||||
EMI: |
| ||||||||||||||||||
EMI Total: | 7,012,088 | ||||||||||||||||||
Total: | 11,320,000 | ||||||||||||||||||
For further information please contact:
Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.comTel: +44 (0) 1483 685 670
Liberum (Nominated Adviser and Broker)
Bidhi BhomaEuan BrownKane CollingsTel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Ellie Blackwell
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
Follow the stocks
